1620 Investment Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

1620 Investment Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$535	–	725
2024 Q4	$535	Hold	1,000	–	–	﹤0.01%	668
2024 Q3	$1.76K	Hold	1,000	–	–	﹤0.01%	576
2024 Q2	$1.17K	Buy	+1,000	New	+$2.5K	﹤0.01%	567

1620 Investment Advisors's MRNS Position: Q1 2025 in Review

1620 Investment Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 1,000 shares — an estimated $535 sold.

1620 Investment Advisors first reported a position in MRNS in Q2 2024 and held it in 3 quarters. The position peaked at $1.76K in Q3 2024. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

1620 Investment Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
1620 Investment Advisors sold 1,000 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $535.
1620 Investment Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q2 2024 and held it in 3 quarters.
1620 Investment Advisors's Marinus Pharmaceuticals, Inc position peaked at $1.76K in Q3 2024.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on 1620 Investment Advisors's 13F filing for Q1 2025, filed 14 May 2025.